About

Overview


At Shattuck Labs, we are pioneering a new class of dual function fusion proteins to create novel therapeutics for patients with cancer and autoimmune disease.

Shattuck was founded in 2016 with the goal of building a fully integrated biotechnology company that creates novel therapeutics for the treatment of cancer and autoimmune disease. At the core of that vision was creating a company that brings together leading scientists, drug manufacturers, physicians, and other professionals to challenge conventional thinking and develop transformational medicines that measurably improve the lives of our patients.

One of the truly differentiating aspects of Shattuck has been the novelty of our proprietary Agonist Redirected Checkpoint (ARC) platform technology. Combining a strong technological foundation with deep professional expertise has allowed us to deliver on our broader corporate mission.  Demonstrating our sense of urgency, we were able to bring our first compound to the clinic within two years of founding the company.

With over 300 ARC compounds produced to date, Shattuck’s research and discovery engine has yielded enormous results. Our discovery production is a cornerstone of all that we do, and we have invested heavily in understanding the science behind all of our compounds. As a result of the significant investment in our platform, we are able to move compounds from bench to clinic in fewer than 18 months, well ahead of industry-standard timelines.

Today we have two product candidates in global clinical trials, treating patients with a high unmet need in cancer. Our constant pursuit of excellence continues to drive us to build a company at the helm of providing truly breakthrough medicines for patients in need.

Mission & Vision

Our vision is to build incredible medicines off the beaten path, by challenging ourselves to think differently.

We work with a sense of urgency, focused on scientific excellence and thoughtful stewardship of resources, to translate innovative ideas into medicines that improve the lives of patients with serious diseases.

mission-vision-img

 

Board of Directors

Taylor H. Schreiber, MD, PhD

Chief Executive Officer, and Co-founder

Taylor is a co-founder of Shattuck Labs and currently serves as Chief Executive Officer and a member of the Board of Directors. Before his appointment as CEO in January 2020, Taylor served as the company’s Chief Scientific Officer. Taylor is the lead inventor of Shattuck’s ARC technology platform. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc. where he was a co-inventor of significant elements of Heat’s ImPACT and ComPACT technology platforms. Taylor was also the co-inventor of Pelican Therapeutics ‘s TNFRSF25 agonist technology where he served as Chairman of the Scientific Advisory Board. Taylor has numerous publications in the field of tumor immunology and immunotherapy, spanning the subjects of cancer vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated immunosuppression and regulatory T cell biology. In 2008, he received the best overall research award at the National Student Research Forum, and in 2011 he was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research. Taylor received both his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from Bucknell University.

Close X

Josiah C. Hornblower

Chairman of the Board, Executive Chairman, and Co-founder

Josiah co-founded Shattuck Labs with Taylor and currently serves as Chairman of the Board, Executive Chairman. Prior to his appointment as Executive Chairman in January of 2020, Josiah served as the founding CEO of the company. He is a private biotechnology entrepreneur and has been involved in successfully starting and operating several biotechnology companies. Prior to co-founding Shattuck, Josiah was a co-founder and former CEO of Pelican Therapeutics, Inc., which was acquired in 2017. He currently sits on the board of Population Bio, a gene discovery company. He also serves as a director of the Daniel K. Thorne Foundation, where he heads the investment committee. Josiah graduated with a Bachelor of Arts degree from Trinity College.

Close X

Tyler Brous

Portfolio Manager, Lennox Capital Partners, LP

Tyler is Managing Director and Portfolio Manager of Lennox Capital Partners, LP, a special situations and value-oriented investment company active in public and private equity. While at Lennox, Tyler spent over a year working at Arog Pharmaceuticals as the acting CFO, leading their capital markets and business development efforts. Prior to joining Lennox, Tyler worked as a senior analyst at YX Funds, a short-only hedge fund in Dallas. In addition, Tyler started his career in the M&A group at Citigroup in New York. Tyler holds a B.S. in Finance and Business Honors from the University of Texas, where he graduated Summa Cum Laude.

Close X

Neil Gibson, PhD

Chief Scientific Officer, Biologics, COI Pharma

Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has held various senior positions within the biotechnology and pharmaceutical industry including senior vice president, BioAtla; chief scientific officer, Regulus Therapeutics; chief scientific officer and oncology therapeutic area head, Pfizer Oncology; and chief scientific officer, OSI Pharmaceuticals. While at Pfizer, Neil was also a member of the Pfizer Oncology Business Unit Executive team. Neil has been involved in the successful discovery, development, and commercialization of four approved oncology drugs, including temozolomide, sorafenib, erlotinib, and crizotinib. While at Regulus he was responsible for leading all research and development efforts resulting in three distinct oligonucleotides being advanced into clinical development and the establishment of human proof of concept with the lead molecule RG-101. Neil has held numerous academic appointments, including associate professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, he has served on the Experimental Therapeutics Study Section of the National Cancer Institute and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Neil earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.

Close X

George Golumbeski, PhD

Former Executive Vice President of Business Development for Celgene

George Golumbeski recently joined GRAIL as President. He has more than 25 years of experience in the biotechnology industry. He currently serves on the Board of Directors of several biotechnology companies, including KSQ Therapeutics, Carrick Therapeutics, Enanta Pharmaceuticals, and MorphoSys. George was most recently Executive Vice President of Business Development for Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. He holds a PhD in genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder. George holds a bachelor’s degree in biology from the University of Virginia

Close X

Michael Lee

Co-founder, Redmile Group, LLC

Mr. Lee is a co-founder and portfolio manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York. Prior to Redmile, he worked as a biotechnology investor at Steeple Capital, and before that at Welch Capital Partners and PThanks Kimrudential Equity Group. Mike holds a B.S. in Molecular and Cellular Biology from the University of Arizona.

Close X

Helen M. Boudreau

Former COO of the Bill & Melinda Gates Medical Research Institute

Helen has 30 years of experience across the biotech, pharmaceuticals, consulting and banking industries. Helen was most recently COO of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech focused on diseases that cause mortality, poverty and inequality in low- and middle-income countries. Previously, she served as CFO for public and private biotechs, and served in senior finance roles at Novartis and Pfizer, including CFO for Novartis Global Oncology. Helen is currently a member of the board of Premier, Inc. (NASDAQ: PINC), a healthcare improvement company, and is also on the boards of two private biotech companies. Helen earned a BA in Economics, summa cum laude, from the University of Maryland, and an MBA from the Darden Graduate School of Business at the University of Virginia.

Close X

Victor Stone MD

Partner, Takeda Ventures, Inc.

Victor Stone (Yoshihide Ishii) joined Takeda Ventures, Inc. (TVI) in January 2020 as Partner, and is based in Cambridge, MA. Prior to joining TVI, Victor was a Director at Whiz Partners, a private equity firm in Tokyo, where he served leading roles in company creation and fund establishment. His responsibilities include board member of Axcelead Drug Discovery Partners, and investment committee member of a joint fund with Takeda. Prior to his transition to business, Victor served in the United States Navy and Marine Corps with multiple combat deployments as a Naval Flight Surgeon. Victor holds an M.D. from Jefferson Medical College, and MBA from Harvard Business School.

Close X
 

Advisory Board

Charles G. Drake, MD, PhD

Columbia University Medical Center

Johann De Bono, MD, PhD

The Institute of Cancer Research

Matthew Hellmann, MD

Memorial Sloan Kettering Cancer Center

Kurt Schalper MD, PhD

Yale School of Medicine

Aurélien Marabelle MD, PhD

Institut Gustave Roussy